Dr Gillian Burgess
Gillian Burgess joined Vertex in 2016 as Vice President, Site Head and Head of Research at Vertex’s Oxford Research Site in the U.K. where she is responsible for discovering new medicines or serious conditions such as chronic pain.
Prior to her appointment at Vertex, she worked in a variety of roles at UCB-Celltech, Pfizer and Novartis helping to bring several compounds to clinical development and to the market. At Pfizer, she was Chief Scientific Officer for the Pain Therapeutic Area, served as Global Therapeutic Area Head for the Gastrointestinal Therapeutic Area and also led Pfizer’s Urology Therapeutic Area. At Novartis she was part of the Neuroscience group.
Dr. Burgess is a member of the MRC DPFS Translational Panel, the MRC Translational Oversight Group and the Wellcome Trust Grant Interview Panel. She is also a member of the British Pharmacological Society Industry committee and sits on the board of the Science Industry Partnership. Dr. Burgess received her Ph.D. from University College London in Pharmacology.